A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Status:
Completed
Trial end date:
2020-01-03
Target enrollment:
Participant gender:
Summary
To assess safety and tolerability, describe the dose-limiting toxicities, determine the
maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose)
in the absence of establishing the MTD, and a recommended dose for further evaluation of
MEDI7247 in patients with selected hematological malignancies who have relapsed after, or are
refractory to prior standard therapy, and for whom there is no standard salvage regimen
available.